What are the side effects of Pimitespib?

In a randomized, Phase III study, pimetibib ( gastrointestinal stromal tumor (GIST) after failure of an approved TKI inhibitor. Pimitespib significantly improved progression-free survival (PFS) as a fourth-line therapy and provided a more significant improvement in OS compared with placebo, equivalent to a 58% reduction in the risk of death, according to the RPSFT model. Pimitinib may therefore be considered a new treatment option for gastrointestinal stromal tumors refractory to standard treatments.

In the clinical trials of pimetibi, the most common (≥30%) treatment-related adverse events (AE) were diarrhea (74.1%) and decreased appetite (31.0%); the most common (≥10%) grade 3 treatment-related adverse events were diarrhea (13.8%), and 5.2% of patients experienced treatment-related adverse events that led to the discontinuation of pimotebi. The symptoms described below are rarely considered initial symptoms of the adverse reactions indicated. If any of these symptoms occur, stop taking this medication and see your doctor immediately. These include severe diarrhea (frequent watery stools, lower abdominal pain, malaise, fever), eye problems (difficulty seeing in the dark, blurred vision, difficulty seeing letters and shapes), bleeding (vomiting blood, black stools, bloody stools, shock). The above symptoms do not describe all adverse reactions of this drug. If Huazhihe notices any symptoms other than those listed above, consult your doctor or pharmacist.

Pimetibi is not marketed in China, and it has been on the market overseas for a short time, and there is little information about its price and other related information.